Trial Profile

A prospective trial to evaluate the effect of Imatinib, Nilotinib and Dasatinib on the pulmonary hypertension of patients with chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Pulmonary hypertension
Focus Therapeutic Use

25 Jun 2017 Results of comparative analysis (n=105) presented at the 22nd Congress of the European Haematology Association.
02 Feb 2016 New trial record
08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com